No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
JNJ Johnson & Johnson
- 147.780
- +2.130+1.46%
Close Jun 20 16:00 ET
- 147.720
- -0.060-0.04%
Post 19:51 ET
355.66BMarket Cap9.79P/E (TTM)
148.080High145.010Low8.75MVolume145.270Open145.650Pre Close1.29BTurnover0.36%Turnover Ratio10.77P/E (Static)2.41BShares170.62652wk High5.08P/B355.01BFloat Cap141.56852wk Low4.76Dividend TTM2.40BShs Float174.925Historical High3.22%Div YieldTTM2.11%Amplitude12.427Historical Low147.195Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike
USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...
Express News | Johnson & Johnson Submits Application to U.S. FDA Seeking Approval of Tremfya® (Guselkumab) for the Treatment of Moderately to Severely Active Crohn's Disease
Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products
Johnson & Johnson (NYSE:JNJ) is reportedly facing a new proposed class action lawsuit seeking damages and medical monitoring for women who have developed or may develop cancer due to using the company
Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease
Thursday, Johnson & Johnson (NYSE:JNJ) released topline data from the pivotal Phase 3 GRAVITI investigational study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adult patients with m
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson with a Overweight and maintains $215 price target.
5 Cheap Stocks Buying Back Shares at Reasonable Prices
Buybacks are in fashion. But at today's valuations, companies could be paying up for their own stock—and that's never a good idea, whether you're a CEO or a retail investor.
Comments
Wonder if anyone is shorting the market now? Whenever there is a small pullback, buyers will step in to push the market up.
It’s crazy how many record highs we have seen this year
$Alibaba(BABA.US$ $Tesla(TSLA.US$ $NIO Inc(NIO.US$ $Super Micro Computer(SMCI.US$ $NVIDIA(NVDA.US$ $ARK 21Shares Bitcoin ETF(ARKB.US$ $Johnson & Johnson(JNJ.US$ $Arm Holdings(ARM.US$ $Alphabet-A(GOOGL.US$ $Apple(AAPL.US$ $Amazon(AMZN.US$ $Netflix(NFLX.US$
It’s crazy how many record highs we have seen this year
$Alibaba(BABA.US$ $Tesla(TSLA.US$ $NIO Inc(NIO.US$ $Super Micro Computer(SMCI.US$ $NVIDIA(NVDA.US$ $ARK 21Shares Bitcoin ETF(ARKB.US$ $Johnson & Johnson(JNJ.US$ $Arm Holdings(ARM.US$ $Alphabet-A(GOOGL.US$ $Apple(AAPL.US$ $Amazon(AMZN.US$ $Netflix(NFLX.US$
From YouTube
1
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
3
$Johnson & Johnson(JNJ.US$ has been under pressure due to talc lawsuits alleging its talc products cause ovarian cancer. In May, the company proposed a $6.5 billion settlement to resolve these claims. Despite this, J&J remains a top dividend stock with a 3.37% yield and has increased its dividend for 62 consecutive years. It has a forward P/E ratio of 13.79 makes it undervalued compared to the broader market. However, the firm does have more than forty new products in late stage clinical trials...
2
Market looked indecisive yesterday as they flipped between red and green zones throughout the trading session.
It seems like the stock market is struggling to find a strong footing as investors await an update from Fed on the latest trajectory and path of interest rates.
Another flat day today?
$Tesla(TSLA.US$ $GameStop(GME.US$ $SPDR S&P 500 ETF(SPY.US$ $S&P 500 Index(.SPX.US$ $Invesco QQQ Trust(QQQ.US$ $Super Micro Computer(SMCI.US$ $NVIDIA(NVDA.US$ $Advanced Micro Devices(AMD.US$ $Microsoft(MSFT.US$ $Meta Platforms(META.US$ $Alphabet-A(GOOGL.US$ $Johnson & Johnson(JNJ.US$ $Amazon(AMZN.US$ $Netflix(NFLX.US$ $Riot Platforms(RIOT.US$
It seems like the stock market is struggling to find a strong footing as investors await an update from Fed on the latest trajectory and path of interest rates.
Another flat day today?
$Tesla(TSLA.US$ $GameStop(GME.US$ $SPDR S&P 500 ETF(SPY.US$ $S&P 500 Index(.SPX.US$ $Invesco QQQ Trust(QQQ.US$ $Super Micro Computer(SMCI.US$ $NVIDIA(NVDA.US$ $Advanced Micro Devices(AMD.US$ $Microsoft(MSFT.US$ $Meta Platforms(META.US$ $Alphabet-A(GOOGL.US$ $Johnson & Johnson(JNJ.US$ $Amazon(AMZN.US$ $Netflix(NFLX.US$ $Riot Platforms(RIOT.US$
From YouTube
2
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
